Haisco: Innovative drug HSK51155 tablet IND application accepted.

Hisun Pharma announced that the company recently received the "Acceptance Notification Letter" of the innovative drug HSK51155 tablets issued by the National Medical Products Administration. This drug is a self-developed oral small molecule non-opioid innovative analgesic drug by the company, belonging to Category 1 chemical drugs. In April 2026, the company reached a cooperation with AbbVie on HSK51155 and related projects, granting it exclusive global rights for development, production, and commercialization, with a potential total transaction amount exceeding 700 million US dollars. The research and development of innovative drugs is high risk, and the company will disclose subsequent progress in a timely manner.